172 related articles for article (PubMed ID: 37657228)
21. Addressing overtreatment of screen detected DCIS; the LORIS trial.
Francis A; Thomas J; Fallowfield L; Wallis M; Bartlett JM; Brookes C; Roberts T; Pirrie S; Gaunt C; Young J; Billingham L; Dodwell D; Hanby A; Pinder SE; Evans A; Reed M; Jenkins V; Matthews L; Wilcox M; Fairbrother P; Bowden S; Rea D
Eur J Cancer; 2015 Nov; 51(16):2296-303. PubMed ID: 26296293
[TBL] [Abstract][Full Text] [Related]
22. What quality-of-life issues do women with ductal carcinoma in situ (DCIS) consider important when making treatment decisions?
Mercieca-Bebber R; King MT; Boxer MM; Spillane A; Winters ZE; Butow PN; McPherson J; Rutherford C
Breast Cancer; 2017 Sep; 24(5):720-729. PubMed ID: 28247220
[TBL] [Abstract][Full Text] [Related]
23. Personalizing the Treatment of Women with Ductal Carcinoma In Situ (DCIS) Using the DCIS Score: A Qualitative Study on Score Use.
O'Brien MA; Paszat L; Makuwaza T; Fong C; Rakovitch E
Curr Oncol; 2024 Feb; 31(2):975-986. PubMed ID: 38392067
[TBL] [Abstract][Full Text] [Related]
24. The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women's characteristics: is it the same?
Théberge I; Vandal N; Guertin MH; Perron L
Breast Cancer Res Treat; 2019 Apr; 174(2):525-535. PubMed ID: 30564969
[TBL] [Abstract][Full Text] [Related]
25. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.
Cuzick J; Sestak I; Pinder SE; Ellis IO; Forsyth S; Bundred NJ; Forbes JF; Bishop H; Fentiman IS; George WD
Lancet Oncol; 2011 Jan; 12(1):21-9. PubMed ID: 21145284
[TBL] [Abstract][Full Text] [Related]
26. The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.
Elshof LE; Schaapveld M; Rutgers EJ; Schmidt MK; de Munck L; van Leeuwen FE; Wesseling J
Breast Cancer Res; 2017 Mar; 19(1):26. PubMed ID: 28274272
[TBL] [Abstract][Full Text] [Related]
27. Should low-risk DCIS lose the cancer label? An evidence review.
Ma T; Semsarian CR; Barratt A; Parker L; Pathmanathan N; Nickel B; Bell KJL
Breast Cancer Res Treat; 2023 Jun; 199(3):415-433. PubMed ID: 37074481
[TBL] [Abstract][Full Text] [Related]
28. Long-term Survival Outcomes of 'Low Risk' Ductal Carcinoma in situ from a Territory-wide Cancer Registry.
Co M; Ngan RKC; Mang OWK; Tam AHP; Wong KH; Kwong A
Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):40-45. PubMed ID: 32713775
[TBL] [Abstract][Full Text] [Related]
29. Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ: A Population-Based Cohort Study.
Sagara Y; Mallory MA; Wong S; Aydogan F; DeSantis S; Barry WT; Golshan M
JAMA Surg; 2015 Aug; 150(8):739-45. PubMed ID: 26039049
[TBL] [Abstract][Full Text] [Related]
30. Recommendations to improve patient-centred care for ductal carcinoma in situ: Qualitative focus groups with women.
Nyhof BB; Wright FC; Look Hong NJ; Groot G; Helyer L; Meiers P; Quan ML; Baxter NN; Urquhart R; Warburton R; Gagliardi AR
Health Expect; 2020 Feb; 23(1):106-114. PubMed ID: 31532871
[TBL] [Abstract][Full Text] [Related]
31. Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?
Rosso KJ; Weiss A; Thompson AM
Surg Oncol Clin N Am; 2018 Jan; 27(1):69-80. PubMed ID: 29132566
[TBL] [Abstract][Full Text] [Related]
32. Ductal carcinoma in situ: treatment or active surveillance?
Kuerer HM
Expert Rev Anticancer Ther; 2015; 15(7):777-85. PubMed ID: 25938920
[TBL] [Abstract][Full Text] [Related]
33. Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
Byng D; Retèl VP; Schaapveld M; Wesseling J; van Harten WH;
Breast Cancer Res Treat; 2021 May; 187(1):187-196. PubMed ID: 33389397
[TBL] [Abstract][Full Text] [Related]
34. Avoiding Overtreatment of Ductal Carcinoma in situ.
van der Borden CL; Stoffers S; Lips EH; Wesseling J
Trends Cancer; 2019 Jul; 5(7):391-393. PubMed ID: 31311652
[TBL] [Abstract][Full Text] [Related]
35. Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis.
Ploumen RAW; Claassens EL; Kooreman LFS; Keymeulen KBMI; van Kats MACE; Gommers S; Siesling S; van Nijnatten TJA; Smidt ML
Breast Cancer Res Treat; 2023 Sep; 201(2):227-235. PubMed ID: 37395816
[TBL] [Abstract][Full Text] [Related]
36. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.
Narod SA; Iqbal J; Giannakeas V; Sopik V; Sun P
JAMA Oncol; 2015 Oct; 1(7):888-96. PubMed ID: 26291673
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case-control and case-case analyses.
Ruszczyk M; Zirpoli G; Kumar S; Bandera EV; Bovbjerg DH; Jandorf L; Khoury T; Hwang H; Ciupak G; Pawlish K; Schedin P; Masso-Welch P; Ambrosone CB; Hong CC
Cancer Causes Control; 2016 Feb; 27(2):183-98. PubMed ID: 26621543
[TBL] [Abstract][Full Text] [Related]
38. Multidisciplinary Shared Decision Making in the Management of Ductal Carcinoma In Situ of the Breast.
Parikh P; Pockaj B; Wasif N; Halyard M; Wong W; Kosiorek HE; Dueck AC; Gray R
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(0 3):S516-21. PubMed ID: 25986869
[TBL] [Abstract][Full Text] [Related]
39. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
Van Bockstal MR; Agahozo MC; Koppert LB; van Deurzen CHM
Int J Cancer; 2020 Mar; 146(5):1189-1197. PubMed ID: 31018242
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis and management of ductal carcinoma in situ (DCIS).
Virnig BA; Shamliyan T; Tuttle TM; Kane RL; Wilt TJ
Evid Rep Technol Assess (Full Rep); 2009 Sep; (185):1-549. PubMed ID: 20629475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
